NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the
“
Company” or “
NurExone”), a
biopharmaceutical company developing biologically-guided exosome
therapy for patients with traumatic spinal cord injuries, is
pleased to announce that it has entered into an investor relations
agreement (the “
Agreement”) with Dr. Reuter
Investor Relations GmbH (“
Dr. Reuter”) to assist
with investor relations and financial publication services for the
European capital markets. The investor relations work focuses
primarily on financial press releases in German-speaking countries
(Germany, Austria and Switzerland).
The Agreement begins on September 1, 2023, and
runs for a minimum of 6 months, until February 29, 2024.
Thereafter, the term is extended by a further 6 months
automatically, unless terminated by either party on one months’
notice. In consideration for the services, NurExone will pay Dr.
Reuter a monthly fee of €3,300. Dr. Reuter does not have any
interest, directly or indirectly, in NurExone or its securities, or
any right or intent to acquire such an interest. Dr. Reuter and
NurExone are at arms-length.
Dr. Reuter Investor Relations, located in
Frankfurt, Germany, has been active in the market since 2006. The
company specializes in the European capital markets and offers
services in the areas of financial press releases, institutional
investor relations and retail investor relations. The company has
extensive and long-standing experience in building sustainable
relationships in capital markets for its clients.
Warrant Amendments
The Company is pleased to announce that the TSX
Venture Exchange has approved the amendment of 12,682,340 common
share purchase warrants of the Company (the
“Warrants”). The amendments
(“Amendments”) consisted of: (i) a reduction of
the exercise price of all Warrants from $1.20 per common share to
$0.38 per common share; (ii) the extension of the expiry date of
1,419,500 Warrants from November 30, 2023 to June 15, 2024; (iii)
the extension of the expiry date of 283,322 Warrants from December
30, 2023 to June 15, 2024; and (iv) the addition of an accelerated
expiration date to all Warrants (the “Accelerated
Expiration”), such that if the closing price of the
Company’s common shares trading on the TSX Venture Exchange exceeds
$0.475 per common share for any ten consecutive trading days
(“Acceleration Event”), the expiration date of the
Warrants will be automatically accelerated to the date that is
thirty days following the Acceleration Event.
Following the Amendments, each Warrant is
exercisable for one common share of the Company at a price of $0.38
per common share at any time prior to June 15, 2024, subject to the
Accelerated Expiration.
“The Warrant Amendments are part of our ongoing
commitment to optimizing our capital structure and ensuring
alignment with the interests of our investors. These Amendments are
a result of extensive discussions and feedback from our
stakeholders,” said Dr. Lior Shaltiel, CEO of NurExone.
“Our decision to amend the Warrants demonstrates
our dedication to creating value and benefit for our shareholders
and Warrant holders. The reduced exercise price aims to make
Warrant exercise more attractive and potentially bolstering the
Company’s balance sheet by up to CAD$4.8 million,” added Eran
Ovadya, CFO of NurExone.
About NurExone Biologic
Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided ExoTherapy to be delivered, non-invasively, to
patients who suffered traumatic spinal cord injuries. ExoTherapy
was conceptually demonstrated in animal studies at the Technion,
Israel Institute of Technology. NurExone is translating the
treatment to humans, and the company holds an exclusive worldwide
license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please
visit www.nurexone.com or follow NurExone on LinkedIn,
Twitter, Facebook, or YouTube.
For more information, please
contact:
Dr. Lior ShaltielChief Executive Officer and
DirectorPhone: +972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation -
CanadaPhone: +1 905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation - Germany
Phone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking
statements” that reflect the Company’s current expectations and
projections about its future development. When used in this press
release, forward-looking statements can be identified by the use of
words such as “may,” or by such words as “will,” “intend,”
“believe,” “estimate,” “consider,” “expect,” “anticipate,” and
“objective” and similar expressions or variations of such words.
Forward-looking statements are, by their nature, not guarantees of
the Company’s future operational or financial performance and are
subject to risks and uncertainties and other factors that could
cause the Company’s actual results, performance, prospects, or
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements. No representation or
warranty is intended with respect to anticipated future results, or
that estimates, or projections will be sustained.
Forward-looking statements are necessarily based
on estimates and assumptions made by us in light of our experience
and perception of historical trends, current conditions, and
expected future developments, as well as the factors we believe are
appropriate. Forward-looking statements in this press release
include, but are not limited to, statements relating to the
Amendments to the Warrants, the capitalization value if the
Warrants are exercised, and the investor relations Agreement.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including the general business and economic conditions of the
industries and countries in which we operate and the general market
conditions.
Many risks, uncertainties, and other factors
could cause the actual results of the Company to differ materially
from the results, performance, achievements, or developments
expressed or implied by such forward-looking statements. These
risks, uncertainties, and other factors include, but are not
limited to, the following: those risk factors identified under the
heading “Risk Factors” pages 29 to 36 of the Company’s Annual
Information Form dated March 30, 2023, a copy of which is available
under the Company’s SEDAR+ profile at www.sedarplus.ca, and other
similar factors that may cause the actual results, performance or
achievements to differ materially from those expressed or implied
in these forward-looking statements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of the press release or as of the date
otherwise specifically indicated herein. Due to risks and
uncertainties, events may differ materially from current
expectations. The Company disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, except as
required pursuant to applicable securities law.
All forward-looking statements contained in the
press release are expressly qualified in their entirety by this
cautionary statement. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
NurExone Biologic (TG:J90)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024